Patterns of 30-Day Post- and on-Treatment Mortality of Patients Undergoing Radiation at a Large Academic Cancer Center: Improving the Quality of Palliative Care

Abstract

received molecular targeted therapy, there were in 3 (1.6%), 3 (1.6%), 4 (2.2%), 2 (1.1%), 3 (1.6%), 0 and 2 (1.1%) patients, respectively. Use of molecular targeted agents and use of VEGFIs showed no significant difference in occurrence of G3 toxicities (3.8% vs 3.7%, pZ1.0, and 7.2% vs 2.8%, pZ0.095). History of previous abdominopelvic surgery (6.9% vs 1.6%, pZ0.009) was only a significant factor. Among patients with molecular targeted agents use, G3 toxicities in patients with VEGFIs use were significantly more than those in patients with other agents use (7.2% vs 1.0%, pZ0.046). Moreover, among patients with VEGFIs use, G3 toxicities in patients with VEGFIs use concurrently or during 7 days before and after RT were significantly more than those in patients with VEGFIs use during other period (18.2% vs 3.3%, pZ0.04). Conclusion: Previous abdominopelvic surgery showed significantly higher occurrence rate of severe GI toxicities. Combination of RT with VEGFIs was significantly riskier than with the other agents. Use of VEGFIs concurrently or during 7 days before and after RT seems to be avoided.